Aligos Shows Promise With Hepatitis B Treatment Data at EASL Congress
Aligos Therapeutics reports positive Phase 1 data for pevifoscorvir sodium, with 40% of patients achieving functional cure-qualifying HBsAg levels.
ALGSpevifoscorvir sodiumantisense oligonucleotide